23794-13-0

Basic information

• Product Name: 2-Bromo-1-(6-chloropyridin-3-yl)-ethanone
• Synonyms: 2-Bromo-1-(6-chloropyridin-3-yl)-ethanone;5-(2-Bromoacetyl)-2-chloropyridine;2-bromo-1-(6-chloro-3-pyridinyl)Ethanone
• CAS NO: 23794-13-0
• Molecular Formula: C₇H₅BrClNO
• Molecular Weight: 234.4777
• Mol File: 23794-13-0.mol

Chemical Properties

• Melting Point: 79-80℃
• Boiling Point: 330.9 °C at 760 mmHg
• Flash Point: 153.9 °C
• Appearance: /
• Density: 1.683
• Vapor Pressure: 0.000161mmHg at 25°C
• Refractive Index: 1.589
• PKA: -2.60±0.10(Predicted)
• CAS DataBase Reference: 2-Bromo-1-(6-chloropyridin-3-yl)-ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromo-1-(6-chloropyridin-3-yl)-ethanone(23794-13-0)
• EPA Substance Registry System: 2-Bromo-1-(6-chloropyridin-3-yl)-ethanone(23794-13-0)

Safety Data

• Hazardous Substances Data: 23794-13-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Bromo-1-(6-chloropyridin-3-yl)-ethanone is used as an intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs with potential therapeutic properties. Its unique structure allows for the creation of various medicinal compounds, enhancing the range of treatments available for different health conditions.
Used in Agricultural Industry:
In the agricultural sector, 2-Bromo-1-(6-chloropyridin-3-yl)-ethanone is employed as an intermediate in the synthesis of agrochemicals, specifically for the development of pesticides and other crop protection agents. Its role in this industry is crucial for enhancing crop yields and ensuring food security by protecting plants from pests and diseases.
Used as a Reagent in Organic Synthesis:
2-Bromo-1-(6-chloropyridin-3-yl)-ethanone is utilized as a reagent in organic synthesis, where it aids in various chemical reactions to produce a wide array of organic compounds. Its presence in these reactions can lead to the formation of new molecules with specific properties, contributing to the advancement of organic chemistry.
Used in the Manufacture of Other Chemical Compounds:
This versatile compound is also used in the production of other chemical compounds, expanding its applications across different industries. Its ability to be integrated into various chemical processes makes it a valuable asset in the creation of a diverse range of products, from specialty chemicals to advanced materials.

InChI:InChI=1/C7H5BrClNO/c8-3-6(11)5-1-2-7(9)10-4-5/h1-2,4H,3H2

Upstream product

• 55676-22-7 3-acetyl-6-chloropyridine 
• 58757-38-3 6-Chloronicotinoyl chloride 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 5006-66-6 6-hydroxynicotinic acid 
• 5326-23-8 6-Chloro-3-pyridinecarboxylic acid 

Relevant articles and documents

Discovery, Structure-Activity Relationship, and Binding Mode of an Imidazo[1,2-a]pyridine Series of Autotaxin Inhibitors

Autotaxin (ATX) is a secreted enzyme playing a major role in the production of lysophosphatidic acid (LPA) in blood through hydrolysis of lysophosphatidyl choline (LPC). The ATX-LPA signaling axis arouses a high interest in the drug discovery industry as it has been implicated in several diseases including cancer, fibrotic diseases, and inflammation, among others. An imidazo[1,2-a]pyridine series of ATX inhibitors was identified out of a high-throughput screening (HTS). A cocrystal structure with one of these compounds and ATX revealed a novel binding mode with occupancy of the hydrophobic pocket and channel of ATX but no interaction with zinc ions of the catalytic site. Exploration of the structure-activity relationship led to compounds displaying high activity in biochemical and plasma assays, exemplified by compound 40. Compound 40 was also able to decrease the plasma LPA levels upon oral administration to rats.

SELECTIVE OCTAHYDRO-CYCLOPENTA[C] PYRROLE NEGATIVE MODULATORS OF NR2B

Compounds that selectively negatively modulate NMDA receptors containing an NR1/NR2B subunit, pharmaceutical compositions comprising the compounds, and methods of treating a disease using the compounds are disclosed. Such diseases include, without limitation, neurological dysfunction such as Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, and seizure disorders; emotional disorders; depression; bipolar disorder; obsessive-compulsive disorder; and other anxiety disorders.

ACETYLENIC MICROBIOCIDES

Compounds of formula (I), wherein the other substituents HetAr, A', R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in claim 1, and their use in compositions and methods for the control and/or prevention of microbial infection, particularly fungal infection, in plants and to processes for the preparation of these compounds.

HETEROCYCLIC AMINE DERIVATIVES

The present invention relates to compounds of formula I wherein A, B, X, Y, Ar, R1, R2, R′, m and n are as defined herein and to pharmaceutical active acid addition salts thereof. Compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds can be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

HETEROCYCLIC AMINE DERIVATIVES

The present invention relates to compounds of formula (I) wherein R1 is hydrogen, lower alkyl, halogen, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen, cyano, nitro, C3-6-cycloalkyl, -CH2-C3-6-cycloalkyl, -O-CH2-C3-6-cycloalkyl, -O-(CH2)2-O-lower alkyl, S(O)2CH3, SF5, -C(O)NH-lower alkyl, phenyl, -O-pyrimidinyl, optionally substituted by lower alkoxy substituted by halogen, or is benzyl, oxetanyl or furanyl; m Ar is aryl or heteroaryl, selected from the group consisting of phenyl, naphthyl, pyrimidinyl, pyridinyl, benzothiazolyl, quinolinyl, quinazolinyl, benzo[d][1.3]dioxolyl, 5,6,7,8- tetrahydro-quinazolinyl, pyrazolyl, pyrazinyl, pyridazinyl, or 1,3,4-oxadiazolyl; Y is a bond, -CH2-, -CH2CH2-, -CH(CF3)- or -CH(CH3)-; R2 is hydrogen or lower alkyl; A is CR or N; and R is hydrogen, cyano, halogen or lower alkyl; R' is hydrogen or halogen; with the proviso that when R' is halogen, then A is CH; B is CH or N; n is 0, 1 or 2; X is a bond, -CH2- or -O-; pharmaceutical active acid addition salts thereof. It has now been found that the compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

3-pyridylethanolamines: Potent and selective human β3 adrenergic receptor agonists

The 3-pyridylethanolamine L-757,793 is a potent β3 AR agonist (EC50 6.3 nM, 70% activation) with 1,300- and 500-fold selectivity over binding to the β1 and β2 ARs, respectively. L-757,793 stimulated lipolysis in rhesus monkeys (ED50 0.2 mg/kg) with a maximum response equivalent to that elicited by isoproterenol.

SUBSTITUTED SULFONAMIDES AS SELECTIVE BETA3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY

Substituted sulfonamides are selective β 3 adrenergic receptor agonists with very little β 1 and β 2 adrenergic receptor activity and as such the compounds are capable of increasing lipolysis and energy expenditure in cells. The compounds thus have potent